Table 5.

Changes in metabolites associated lysophospholipids in serum of the Placebo and the 600mg TT groups at 0 and 12 wk.

Sub pathway	Biochemical name	Placebo: Ratio 12 wk/0 wk	600mg TT: Ratio 12 wk/0 wk
Lysophospholipids	2-palmitoyl-GPC (16:0)	1.00	1.17*
	1-palmitoleoyl- GPC (16:1)	1.06	1.20*
	2-palmitoleoyl- GPC (16:1)	1.13	1.24*
	1-stearoyl-GPC (18:0)	1.09*	1.09*
	1-oleoyl-GPC (18:1)	1.09*	1.13*
	1-linolenoyl-GPC (18:3)	1.37*	1.16
	1-arachidonoyl- GPC (20:4n6)	1.03	1.07*
	1-stearoyl-GPE (18:0)	1.12*	1.07
	1-oleoyl-GPE (18:1)	1.21*	1.05
	1-linoleoyl-GPE (18:2)	1.15*	0.98
	1-palmitoyl-GPI (16:0)	1.04	1.57*
	1-stearoyl-GPI (18:0)	1.05	1.46*
	1-oleoyl-GPI (18:1)	1.19	1.64*
	1-linoleoyl-GPI (18:2)	1.01	1.24*
	1-arachidonoyl- GPI (20:4)	0.94	1.29*

Metabolite values are expressed as the ratio of Placebo 12 wk/0 wk which is the fold change of the Placebo at 12 wk compared to the Placebo at 0 wk. Similarly, the ratio of 600mg TT 12 wk/0 wk which is the fold change of the 600mg TT at 12 wk compared to the 600mg TT at 0 week. A ratio >1 indicates a value larger for the 12-wk collection (Placebo 12 wk or 600mg TT 12 wk) and <1 the value for the 12-wk collection (Placebo 12 wk or 600mg TT 12 wk) is lower compared to the 0-wk collection (Placebo 0 wk or 600mg TT 0 wk). Statistical differences are indicated for the values at baseline and after 12 weeks within the same treatment group or placebo (n = 20).

^*Indicates p < 0.05. GPC, glycerophosphocholine; GPE, glycerophosphoethanolamine; GPI, glycosylphosphatidylinositol.